Results 101 to 110 of about 1,236,932 (359)
Lung volumes identify an at-risk group in persons with prolonged secondhand tobacco smoke exposure but without overt airflow obstruction. [PDF]
, 2018 IntroductionExposure to secondhand smoke (SHS) is associated with occult obstructive lung disease as evident by abnormal airflow indices representing small airway disease despite having preserved spirometry (normal forced expiratory volume in 1 s-to ...Arjomandi, Mehrdad, Blanc, Paul D, Bos, Bruce, Elicker, Brett, Geerts, Jeroen, Gold, Warren M, Keene, Jason, Stiner, Rachel K, van Koeverden, Ian, Zeng, Siyang +9 morecore +2 more sourcesMethylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies
Molecular Oncology, EarlyView.We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy. Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck +12 morewiley +1 more sourceMacrophage phenotype is associated with disease severity in preterm infants with chronic lung disease. [PDF]
, 2014 The etiology of persistent lung inflammation in preterm infants with chronic lung disease of prematurity (CLD) is poorly characterized, hampering efforts to stratify prognosis and treatment. Airway macrophages are important innate immune cells with roles A Kotiranta-Ainamo, AE Currie, BJ Zeligs, BJ Zeligs, BW Kramer, BW Parks, C Haslett, D Chantry, David H. Dockrell, DH Bowden, E Alenghat, E Forster-Waldl, Eamon P. McGreal, ER Unanue, F Genel, F Kanakoudi-Tsakalidou, G Fingerle, G Kurland, H Arai, HM Marriott, HW Ziegler-Heitbrock, HW Zimmermann, HY Huh, Ian Sabroe, J Grigg, J Savill, JA Bellanti, JM Cavaillon, JM Grigg, K Asada, K Dhaliwal, L Landsman, L Ziegler-Heitbrock, LJ Van Marter, Lynne R. Prince, M Daigneault, M Iwahashi, M Zhang, ML Huynh, Moira K. Whyte, NE Alexis, Nicola C. Maxwell, NS Dessardo, O Grip, Oliver Eickelberg, P Antal-Szalmas, PL Davies, R Andreesen, RL Kradin, S Knapp, S Kotecha, S Kotecha, S Rosseau, SA Renshaw, Sailesh Kotecha, SB Gordon, Sharonjit K. Gill, T Ganz, TS Blackwell, U Hallwirth, VA Fadok, WS Driscoll +61 morecore +4 more sourcesStrength through diversity: how cancers thrive when clones cooperate
Molecular Oncology, EarlyView.Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra +3 morewiley +1 more sourcePerspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology
Molecular Oncology, EarlyView.Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...Marius Ilié, Umberto Malapelle, Catherine Alix‐Panabières, Claus Lindbjerg Andersen, Sandra Chlebowski, Vivien Lake, Caroline Lacoux, Virginie Lespinet‐Fabre, Olivier Bordone, Simon Heeke, Christophe Bontoux, Ellen Heitzer, Klaus Pantel, Paul Hofman +13 morewiley +1 more sourceInhaled corticosteroids versus long-acting beta -agonists for chronic obstructive pulmonary disease (Review). [PDF]
, 2011 Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler.Agarwal, Anderson, Appleton, Barnes, Borgstrom, Borgstrom, Boyd, Burge, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverly, Campbell, Campell, Cazzola, Cazzola, Celli, Celli, Celli, Celli, Corhay, Dahl, Della Cioppa, Egede, Ferguson, Ferguson, Gosman, Greefhorst, Halpin, Halpin, Halpin, Hanania, Hanania, Hanania, Higgins, Horstman, Hunjan, Hunjan, Hunjan, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Keene, Korsgaard, Kristufek, Lange, Lofdahl, Lofdahl, Lofdahl, Lofdahl, Lyseng-Williamson, Mahler, Mahler, Mahler, McGarvey, Milanowski, Nannini, Nannini, Nannini Luis, Nitschmann, Pauwels, Pauwels, Reynolds, Rodrigo, Rodrigo, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Szafranski, Vestbo, Vestbo, Vestbo, Vestbo, Vestbo, Yang +105 morecore +2 more sourcesBaseline CT-Based Whole Lung Radiomics Phenotype Predicts the Survival of Chronic Obstructive Pulmonary Disease
, 2023 TaoHu Zhou, Xiuxiu Zhou, Jiong Ni, Shaofeng Duan, Yu Guan, Yanyan Wu, Xin’ang Jiang, Xiaoqing Lin, Jie Li, Yi Xia, Xiang Wang, Yun Wang, Wenjun Huang, Wenting Tu, Peng Dong, Zhaobin Li, Shiyuan Liu, Li Fan +17 moreopenalex +1 more sourceMonitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien +35 morewiley +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more source
